Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Bart Staels"'
Autor:
Patrice Marques, Carlos Villarroel-Vicente, Aida Collado, Ainhoa García, Laura Vila, Isabelle Duplan, Nathalie Hennuyer, Francisco Garibotto, Ricardo D. Enriz, Catherine Dacquet, Bart Staels, Laura Piqueras, Diego Cortes, María-Jesús Sanz, Nuria Cabedo
Publikováno v:
Pharmacological Research. 187:106638
Selective peroxisome proliferator-activated receptors (PPARs) are widely used to treat metabolic complications; however, the limited effect of PPARα agonists on glucose metabolism and the adverse effects associated with selective PPARγ activators h
Autor:
Nathalie Hennuyer, Nicolas Lebegue, Morgan Le Naour, Monique Beucher-Gaudin, Daniel-Henri Caignard, Pascal Carato, Catherine Dacquet, Bart Staels, Veronique Leclerc, Patricia Melnyk, Aurelie Hurtevent
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry
Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35 (1), pp.524-538. ⟨10.1080/14756366.2020.1713771⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2020, Journal of Enzyme Inhibition and Medicinal Chemistry, 35 (1), pp.524-538. ⟨10.1080/14756366.2020.1713771⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2020, 35 (1), pp.524-538. ⟨10.1080/14756366.2020.1713771⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 35, Iss 1, Pp 524-538 (2020)
Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35 (1), pp.524-538. ⟨10.1080/14756366.2020.1713771⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2020, Journal of Enzyme Inhibition and Medicinal Chemistry, 35 (1), pp.524-538. ⟨10.1080/14756366.2020.1713771⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Informa Healthcare, 2020, 35 (1), pp.524-538. ⟨10.1080/14756366.2020.1713771⟩
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 35, Iss 1, Pp 524-538 (2020)
International audience; A series of nitrogen heterocycles containing α-ethoxyphenylpropionic acid derivatives were designed as dual PPARα/γ agonist ligands for the treatment of type 2 diabetes (T2D) and its complications. 6-Benzoyl-benzothiazol-2-
Autor:
Julie Charton, Clara Maillard, Chau Phi Dinh, Adrien Herledan, Florence Leroux, Catherine Piveteau, Benoit Deprez, Isabelle Duplan, Nicolas Kraupner, Nathalie Hennuyer, Xiaoan Wen, Rebecca Deprez-Poulain, Damien Bosc, Sandrine Warenghem, Bart Staels, Valérie Landry
Publikováno v:
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 2021, pp.113982. ⟨10.1016/j.ejmech.2021.113982⟩
European Journal of Medicinal Chemistry, Elsevier, 2021, pp.113982. ⟨10.1016/j.ejmech.2021.113982⟩
European Journal of Medicinal Chemistry, 2021, pp.113982. ⟨10.1016/j.ejmech.2021.113982⟩
European Journal of Medicinal Chemistry, Elsevier, 2021, pp.113982. ⟨10.1016/j.ejmech.2021.113982⟩
International audience; Insulin degrading enzyme (IDE) is a zinc metalloprotease that cleaves numerous substrates among which amyloid-β and insulin. It has been linked through genetic studies to the risk of type-2 diabetes (T2D) or Alzheimer's disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ed5fe0bfb1f46856b4bc660d9fb3a7
https://hal.science/hal-03430475
https://hal.science/hal-03430475
Autor:
Zsolt Bocskei, Corinne Rocher, Andreas Evers, Ralf Elvert, Tim Klöckener, Martin Bossart, Claire Kammermeier, Michael Wagner, Katrin Lorenz, Aimo Kannt, Bart Staels, Vincent Mikol, Jean-Claude Guillemot, Wolfgang Hennerici, Andreas Nygaard Madsen, Torsten Haack, François Pattou
Publikováno v:
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2020, Online ahead of print. ⟨10.1111/dom.14035⟩
Diabetes, Obesity and Metabolism, 2020, Online ahead of print. ⟨10.1111/dom.14035⟩
Diabetes, Obesity and Metabolism, Wiley, 2020, Online ahead of print. ⟨10.1111/dom.14035⟩
Diabetes, Obesity and Metabolism, 2020, Online ahead of print. ⟨10.1111/dom.14035⟩
Aims To test specific mono‐agonists to the glucagon‐like peptide‐1 receptor (GLP‐1R), glucagon receptor (GCGR) and glucose‐dependent insulinotropic peptide receptor (GIPR), individually and in combination, in a mouse model of diet‐induced
Autor:
Dicky Struik, Niels Hellings, Anja Kerksiek, Melissa Schepers, Ilse Dewachter, Frank P.J. Leijten, Johan W. Jonker, Yupyn Chintapakorn, Thiti Suttiyut, Monique T. Mulder, Hong-Bing Liu, Tim Vanmierlo, Eric J.G. Sijbrands, Jochen Walter, Surachai Pornpakakul, Jeroen F. J. Bogie, Dieter Lütjohann, Assia Tiane, Bart Staels, Ann Cuypers, Albert K. Groen, Jerome J. A. Hendriks, Cindy Hoeks, Pilar Martinez-Martinez
Publikováno v:
Scientific reports, 9(1):4908. Nature Publishing Group
Scientific Reports
Scientific Reports, 9:4908. Nature Publishing Group
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
Scientific Reports, 9(1):4908. Nature Publishing Group
Scientific Reports
Scientific Reports, 9:4908. Nature Publishing Group
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
Scientific Reports, 9(1):4908. Nature Publishing Group
Activation of liver X receptors (LXRs) by synthetic agonists was found to improve cognition in Alzheimer’s disease (AD) mice. However, these LXR agonists induce hypertriglyceridemia and hepatic steatosis, hampering their use in the clinic. We hypot
Autor:
Thomas Hubert, Lorea Zubiaga, Florent Auger, Caroline Bonner, Mehdi Daoudi, François Pattou, Olivier Briand, Bart Staels, L.B. Bindels, Violeta Raverdy, Daniela Zdzieblo, Blandine Laferrère, Nathalie M. Delzenne, Markus Müehlemanns, Gianni Pasquetti, Bernard Thorens, Veronique Touche, Audrey Quenon, Huglo Damien, Sophie Lestavel, Camille Marciniak, Benoit Deprez, Hermann Koepsell, Marie C. Vatyghem, Julie Kerr-Conte, Julien Thevenet
Publikováno v:
SSRN Electronic Journal.
Metformin (MET) is the most prescribed antidiabetic drug but its mechanism of action remains elusive. Recent clinical data point to the gut as MET primary target. In the present study we explored the effect of MET in the gut transport machinery. Usin
Autor:
Barbara D. Pachikian, Chantal Dessy, Sophie Lestavel, Ahmed Essaghir, Emilie Catry, Hubert Plovier, Caroline Bouzin, Laure B. Bindels, Jean-François Goossens, Anne Tailleux, Nathalie M. Delzenne, Bart Staels, Jean-Baptiste Demoulin, Irina Lobysheva, Audrey M. Neyrinck, Patrice D. Cani
Publikováno v:
Gut
Gut, 2018, Gut, 67 (2), pp.271-283. ⟨10.1136/gutjnl-2016-313316⟩
Gut, p. [1-14] (2017)
Gut, Vol. 67, no.2, p. 271-283 (2018)
Gut, 2018, Gut, 67 (2), pp.271-283. ⟨10.1136/gutjnl-2016-313316⟩
Gut, p. [1-14] (2017)
Gut, Vol. 67, no.2, p. 271-283 (2018)
ObjectiveTo investigate the beneficial role of prebiotics on endothelial dysfunction, an early key marker of cardiovascular diseases, in an original mouse model linking steatosis and endothelial dysfunction.DesignWe examined the contribution of the g
Autor:
Hélène Gras-Masse, Jamal Elbakali, Cyril Ronco, Nathalie Hennuyer, Marion Gauriot, Julie Charton, Wenguang G. Liang, Xiaoan Wen, Antoine Heninot, Florence Leroux, Julie Dumont, Jane Totobenazara, Valérie Landry, Xavier Marechal, Wei-Jen Tang, Adrien Herledan, Virginie Pottiez, Bart Staels, Rebecca Deprez-Poulain, Damien Bosc, Benoit Deprez
Publikováno v:
European Journal of Medicinal Chemistry. 90:547-567
Insulin degrading enzyme (IDE) is a zinc metalloprotease that degrades small amyloid peptides such as amyloid-β and insulin. So far the dearth of IDE-specific pharmacological inhibitors impacts the understanding of its role in the physiopathology of
Publikováno v:
Cellular and Molecular Life Sciences. 72:1631-1650
Bile acids (BAs) are amphipathic molecules produced from cholesterol by the liver. Expelled from the gallbladder upon meal ingestion, BAs serve as fat solubilizers in the intestine. BAs are reabsorbed in the ileum and return via the portal vein to th
Autor:
Lesley J. Millatt, Dean W. Hum, Bertrand Cariou, Géraldine Rigou, Philippe Delataille, Valérie Daix, Rémy Hanf, Bernard Noël, Bart Staels
Publikováno v:
Diabetes and Vascular Disease Research. 11:440-447
We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta (PPARα/δ) agonist, in the db/ db mouse model of diabetes. Mice were treated with vehicle, GFT505, PPARγ agonist rosigli